Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection.

ABSTRACT:

Background

Advanced liver disease due to hepatitis C virus (HCV) is a leading cause of human immunodeficiency virus (HIV)-related morbidity and mortality. There remains a need to develop noninvasive predictors of clinical outcomes in persons with HIV/HCV coinfection.

Methods

We conducted a nested case-control study in 126 patients with HIV/HCV and utilized multiple quantitative metabolomic assays to identify a prognostic profile that predicts end-stage liver disease (ESLD) events including ascites, hepatic encephalopathy, hepatocellular carcinoma, esophageal variceal bleed, and spontaneous bacterial peritonitis. Each analyte class was included in predictive modeling, and area under the receiver operator characteristic curves (AUC) and accuracy were determined.

Results

SUBMITTER: Naggie S 

PROVIDER: S-EPMC7661766 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature